Hepatitis Monthly

Published by: Kowsar

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study

Meisam Mahdavi 1 , Houshang Amirrasouli 1 , * , Seyed Moayed Alavian 2 , 3 , Bita Behnava 3 , Faranak Kazerouni 1 , Maryam Keshvari 4 , Saeed Namaki 1 , Mohammad Gholami Fesharaki 5 , Hooman Rahimipour 6 , Jahangir Mohammadzade 1 , Farahnaz Zohrehbandian 7 and Fazel Mahdavipour 8
Authors Information
1 Department of Laboratory Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 2Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Middle East Liver Diseases Center (MELD Center), Tehran, IR Iran
4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
5 Biostatistic Department, Faculty of Medicine, Tarbiat Modares University, Tehran, IR Iran
6 Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
7 Department of Microbiology, Faculty of Basic Sciences, Islamic Azad University, North Tehran Branch, Tehran, IR Iran
8 Faculty of Medicine, Ilam University of Medical Sciences, Ilam, IR Iran
Article information
  • Hepatitis Monthly: November 01, 2013, 13 (11); e11903
  • Published Online: November 23, 2013
  • Article Type: Research Article
  • Received: May 1, 2013
  • Revised: July 21, 2013
  • Accepted: September 28, 2013
  • DOI: 10.5812/hepatmon.11903

To Cite: Mahdavi M, Amirrasouli H, Alavian S M, Behnava B, Kazerouni F, et al. Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study, Hepat Mon. 2013 ;13(11):e11903. doi: 10.5812/hepatmon.11903.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Sirianni MC, Campagna M, Scaramuzzi D. Control of human herpes virus type 8-associated diseases by NK cells. Ann N Y Acad Sci. 2007; 1096: 37-43
  • 2. Trambas CM, Griffiths GM. Delivering the kiss of death. Nat Immunol. 2003; 4: 399-403
  • 3. Shen DT, Ma JS, Mather J, Vukmanovic S, Radoja S. Activation of primary T lymphocytes results in lysosome development and polarized granule exocytosis in CD4 + and CD8 + subsets, whereas expression of lytic molecules confers cytotoxicity to CD8 + T cells. J Leukoc Biol. 2006; 80: 827-837
  • 4. Ménager MM, Ménasché G, Romao M, Knapnougel P, Ho CH, Garfa M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol. 2007; 8: 257-267
  • 5. Fan Z, Zhang Q. Molecular mechanisms of lymphocyte-mediated cytotoxicity. Cell Mol Immunol. 2005; 2(4): 259-64[PubMed]
  • 6. Catalfamo M, Henkart PA. Perforin and the granule exocytosis cytotoxicity pathway. Curr Opin Immunol. 2003; 15: 522-527
  • 7. Cooksley G, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alfa 2a (40KDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10: 298-305
  • 8. Lau GK, Piratvisuth T, Xian Luo K, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352(26): 2682-2695
  • 9. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2001; 34: 1225-1241
  • 10. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology. 2001; 120: 1828-1853
  • 11. Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu Rev Med. 1981; 32: 1-11[DOI]
  • 12. Marcellin P, Bonino F, Lau OK, Farci P, Yurdaydin C, Piratvisuth T, et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa 2a lamivudine: 3 years follow-up results [abstract 53]. J Hepatol. 2007; 46(Suppl 1)
  • 13. Bonino F, Chiaberge E, Maran E, Piantino P. Serological markers of HBV infectivity. Ann. Ist. Super. Sanita. 1987; 14(217-230)
  • 14. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B:summary of a clinical research workshop. Hepatology. 2007; 45: 1056–1075
  • 15. Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. Iran J Clin Infect Dis. 2010; 5(1): 51-61
  • 16. Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, et al. Granzyme B-mediated cytochrome C release is regulated by the Bcl-2 family members bid and Bax. J Exp Med. 2000; 192: 1391-1402
  • 17. Bots M, Medema JP. Granzymes at a glance. J Cell Sci. 2006; 119: 5011-5014[DOI]
  • 18. Uellner R, Zvelebil MJ, Hopkins J, Jones J, MacDougall LK, Morgan BP, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J. 1997; 16: 7287-7296
  • 19. Kaser A, Enrich B, Ludwiczek O, Vogel W, Tilg H. Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. Clin Exp Immunol. 1999; 118(1): 71-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments